WeWork and Theranos were priced badly in private markets, which is a completely different kind of fraud/misleading than after the IPO, when it's a matter of pub

WeWork and Theranos were priced badly in private markets, which is a completely different kind of fraud/misleading than after the IPO, when it's a matter of public communications. Before IPO, I think almost every fraud is unique, even if they have common themes ... but after IPO I think it's more similar to just hype-man using PR and media to keep retail investors avoiding the reality of the balance sheet.